Anna Dvorkin-Gheva

Title: Innovations of Anna Dvorkin-Gheva

Introduction

Anna Dvorkin-Gheva is an accomplished inventor based in Burlington, CA. She has made significant contributions to the field of immunology, particularly in the engineering of T cells for enhanced therapeutic applications. With a total of 3 patents, her work is paving the way for advancements in cancer treatment and immune response modulation.

Latest Patents

Among her latest patents is the "T cell-antigen coupler with Y182T mutation and methods of uses thereof." This invention describes a trifunctional molecule that includes a target-specific ligand, a ligand that binds a protein associated with the T cell receptor (TCR) complex, and a T cell receptor signaling domain polypeptide. The ligand that binds to the TCR complex is UCHT1 with a Y182T mutation. Engineering T cells with this novel receptor allows for antigen-specific activation of various T cell functions, including cytokine production, degranulation, and cytolysis.

Career Highlights

Anna Dvorkin-Gheva is currently affiliated with McMaster University, where she continues her research and development in the field of immunotherapy. Her innovative approaches have garnered attention and recognition within the scientific community.

Collaborations

She has collaborated with notable colleagues, including Christopher W. Helsen and Jonathan Lorne Bramson, to further enhance the impact of her research.

Conclusion

Anna Dvorkin-Gheva's contributions to the field of immunology through her patents and collaborative efforts highlight her role as a leading inventor in advancing T cell engineering. Her work is instrumental in developing new therapeutic strategies for cancer treatment and immune system modulation.